Search

Your search keyword '"Rolling C"' showing total 7 results
Start Over Author "Rolling C" Search Limiters Peer Reviewed
7 results on '"Rolling C"'

1. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

Author

Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., and Garralda, E.

Published
2022
Full Text
View/download PDF

5. TEMPORARY REMOVAL: PO-31: The small-molecule FXIa inhibitor, BMS-26208, prevents tumor cell-induced coagulation activation predominantly in tumor entities with lower tissue factor (TF) expression.

Author

Mäder, J., Voigtlaender, M., Rolling, C., Quick, H., Schulenkorf, A., Lehr, C., Bokemeyer, C., Beckmann, L., and Langer, F.

Subjects
*BLOOD coagulation, *TUMORS, *TISSUES, *SCHOLARLY periodical corrections, *CELL adhesion molecules
Abstract

The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. 98LBA Late Breaking - Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

Author

Macchini, M., Garralda, E., Fiedler, W., Del Conte, G., Rolling, C., Kebenko, M., Klinghammer, K.F., Ahrens-fath, I., Habel, B., Baumeister, H., Zurlo, A., and Ochsenreiter, S.

Subjects
*PANITUMUMAB, *THERAPEUTIC use of monoclonal antibodies, *CONFERENCES & conventions, *TUMORS, *EPIDERMAL growth factor receptors
Published
2020
Full Text
View/download PDF

7. SO-010 - Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.

Author

Garralda, E., Fiedler, W., Matos, I., Rolling, C., Kebenko, M., Klinghammer, K., Conte, G., Raspagliesi, F., Habel, B., Baumeister, H., Ochsenreither, S., and Zurlo, A.

Subjects
*COLORECTAL cancer, *EPIDERMAL growth factor receptors, *TUMORS
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results